External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

EASD 2026

-
09:45 AM
Duration 60mins Milan, Italy
CT-388, a glp-1/gip receptor agonist, reduced cv prognostic markers of central and visceral adiposity in adults with obesity/overweight with >=1 weight-related comorbidity in a phase 2 trial
Helen Colhoun, Javed Butler, Ji (Emmy) Cheng, Julie Ishida, Macy Gipson, Nikolaus Marx, Odd Erik Johansen, Xuwei Hou
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 60mins Milan, Italy
Behavioral Insulin Timing: The Impact Of Nutrient Types And CGM Baselines On Bolus Omission And Delay
Cristian Galán Augé, Michael Mitter, Amalia Ruiz Serrano, Ezgi Cinar
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 4mins Milan, Italy
CT-388, a glp-1/gip receptor agonist, reduced cv prognostic markers of central and visceral adiposity in adults with obesity/overweight with >=1 weight-related comorbidity in a phase 2 trial
Helen Colhoun, Javed Butler, Ji (Emmy) Cheng, Julie Ishida, Macy Gipson, Nikolaus Marx, Odd Erik Johansen, Xuwei Hou
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
11:00 AM
Duration 60mins Milan, Italy
CT-388, a GLP-1/GIP receptor agonist, reduced cardiovascular risk factors in people with overweight/obesity in a phase 2 trial
Carel Le-Roux, Alexandra Steinberg, Dan Lender, Esther Shearer-Kang, Harold Bays, Ildiko Lingvay, Jeffrey Willis, Ji (Emmy) Cheng, Kenneth Kim, Odd Erik Johansen, Sureka Bollepalli
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 60mins Milan, Italy
CT-388, a GLP-1/GIP receptor agonist, reduced vascular, haemodynamic and body fluid parameters in people with overweight/obesity in a Phase 2 trial
Odd Erik Johansen, Diego Rebella, Javed Butler, Ji (Emmy) Cheng, Macy Gipson, Mark Petrie, Nikolaus Marx, Xuwei Hou
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 60mins Milan, Italy
Anaerobic Activity Shows The Largest Reduction In Glycaemic Variability In A Real-World CGM Analysis Of 159,404 Exercise Events In Type 2 Diabetes
Josip Zivkovic, Othmar Moser, Michael Mitter, Ajandek Peak, Johanna Kober
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 4mins Milan, Italy
CT-388, a GLP-1/GIP receptor agonist, reduced cardiovascular risk factors in people with overweight/obesity in a phase 2 trial
Carel Le-Roux, Alexandra Steinberg, Dan Lender, Esther Shearer-Kang, Harold Bays, Ildiko Lingvay, Jeffrey Willis, Jennifer Green, Ji (Emmy) Cheng, Kenneth Kim, Odd Erik Johansen, Sureka Bollepalli
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 4mins Milan, Italy
CT-388, a GLP-1/GIP receptor agonist, reduced vascular, haemodynamic and body fluid parameters in people with overweight/obesity in a Phase 2 trial
Odd Erik Johansen, Diego Rebella, Javed Butler, Ji (Emmy) Cheng, Macy Gipson, Mark Petrie, Nikolaus Marx, Xuwei Hou
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
12:40 PM
Duration 60mins Milan, Italy
Petrelintide, a human amylin analog for the treatment of obesity: results from a phase 2, randomised, double-blind, placebo-controlled trial (ZUPREME 1)
W. Timothy Garvey, Jamy Ard, Lisa Connery, Juan Pablo Frias, Carel le Roux, Malene Dinesen, Berith Fredsted Hagen, Louise Larsen, Dan Hesse, Steven R. Smith
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
01:30 PM
Duration 10mins Milan, Italy
CT-388, a cAMP Signal-biased GLP-1/GIP Receptor Agonist, Achieves Clinically Meaningful Weight Loss in People With Overweight/Obesity: a 48-weeks Phase 2 Study
Ildiko Lingvay, Alexandra Steinberg, Ania Jastreboff, Carel Le Roux, Dan Lender, Esther Shearer-Kang, Giuseppe Palermo, Harold Bays, Jeffrey Willis, Kenneth Kim, Manu Chakravarthy, Sureka Bollepalli
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
10:45 AM
Duration 60mins Milan, Italy
Safety and pharmacodynamics of CT-996, an oral small molecule, cAMP signal-biased GLP-1 receptor agonist, over 4 weeks in adults with overweight/obesity and type 2 diabetes
Manu Chakravarthy, Dietmar Volz, Federico A Argüelles-Tello, Leyla L Sanchez-Sanchez, Stacey Toussaint Touson
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 60mins Milan, Italy
Heterogeneous Post‐Exercise Hypo‐ And Hyperglycemia Patterns Reveal The Need For Individualized Support In People With Diabetes
Josip Zivkovic, Elisabeth Kneip, Ajandek Peak, Johanna Kober
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 4mins Milan, Italy
Safety and pharmacodynamics of CT-996, an oral small molecule, cAMP signal-biased GLP-1 receptor agonist, over 4 weeks in adults with overweight/obesity and type 2 diabetes
Manu Chakravarthy, Dietmar Volz, Federico A Argüelles-Tello, Leyla L Sanchez-Sanchez, Stacey Toussaint Touson
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
12:00 PM
Duration 60mins Milan, Italy
Over-Bolusing Before Exercise: A Cohort-Level Analysis Of Hypoglycemia Risk In People With Diabetes
Eemeli Leppäaho, Ajandek Peak, Johanna Kober
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 60mins Milan, Italy
Persistent Postprandial Hyperglycemia In Highly Engaged Digital Therapeutics Users: Identifying Gaps In Meal Management
Ezgi Cinar, Cristian Galán Augé, Michael Mitter, Amalia Ruiz Serrano
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Coming soon